Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Soligenix Inc SNGX

Healthcare Biotechnology
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SNGX)

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

PR Newswire 9 days ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Accesswire 13 days ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

PR Newswire November 14, 2024

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

PR Newswire November 8, 2024

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

GlobeNewswire October 24, 2024

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

PR Newswire October 22, 2024

Soligenix Invited to Present at Upcoming Investor Conferences

PR Newswire October 16, 2024

HyBryte(TM) Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

PR Newswire October 7, 2024

Soligenix Announces Partnership with Sterling Pharma Solutions

PR Newswire October 3, 2024
View More News ››

Opinion & Analysis (NDAQ:SNGX)

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

Streetwise Reports August 22, 2019

NIH Selects Biopharma's Lead Asset for Commercialization Accelerator Program

Streetwise Reports September 27, 2018

Soligenix's diversified pipeline advances on all fronts

The Life Sciences Report August 31, 2016

VIDEO: Focused on Rare Disease Therapies

BTV-Business Television June 28, 2016

Soligenix develops defenses against bioterrorism SNGX

The Life Sciences Report June 15, 2016

Soligenix fosters potent pipeline of orphan disease compounds in areas of unmet medical need

The Life Sciences Report April 27, 2016
View More Opinion ››

Bullboard Posts (NDAQ:SNGX)

SGNX WHO Says Risk of Marburg Virus Outbreak

SGNX WHO Says Risk of Marburg Virus Outbreak Very High at National Level
10QKing - October 3, 2024

Nova Minerals and Soligenix Interviews to Air on the RedChip

JUST IN: $SNGX Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL ...
whytestocks - September 20, 2024

Soligenix, Inc. (NASDAQ:SNGX): Positive Interim Results for

http://beyondspx.com/2024/08/02/soligenix-inc-nasdaqsngx-positive-interim-results-for-hybryte-in-investigator-initiated-study-in-ctcl...
MikeTester - August 3, 2024

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix'

BREAKING NEWS: $SNGX PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte(TM)- Lighting the Way Towards...
whytestocks - July 15, 2024

Soligenix Announces Recent Accomplishments And First Quarter

News; $SNGX Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsSoligenix Announces Recent...
whytestocks - May 10, 2024

Soligenix Extends Patent Protection for its Filovirus Vaccin

JUST IN: $SNGX Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaSoligenix...
whytestocks - April 25, 2024
View more Bullboard ››

K9 Gold Corp

K9 Gold Corp

K9 Gold Corp. is engaged in the business of identification, acquisition and exploration of mineral interests. The Company’s ...
View More »